Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Response to GFIP/BDC

From: Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer

Response No. of Patients Percentage Median Duration of Response (range)
Partial 11 55% 6 months (1.5 – 20)
Stable 7 35% 4.5 (2 – 6)
Progressive 2 10% N/A